- Novavax Inc NVAX reaffirmed its partnership with South Korean firm SK Bioscience Co Ltd to expand its production of vaccines, including Novavax's protein-based COVID-19 vaccine candidate NVX-CoV2373.
- In February, Novavax had entered into a license agreement with the South Korean manufacturer to produce 40 million doses of the COVID-19 vaccine for the country.
- SK bioscience initiated the rolling submission process for NVX-CoV2373 to South Korea's Ministry of Food and Drug Safety in April 2021.
- Price Action: NVAX shares closed at $143.01 on Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
